Astellas

News

Astellas bets on Vir cancer drug, and other licensing deals

Our latest round-up of pharma licensing deals features assets from Vir Biotech, Harbour BioMed, Unnatural Products, Genhouse, and CSL.

News

Zydus follows Lupin with Myrbetriq settlement deal

Zydus has joined Lupin in agreeing to settle patent litigation with Astellas on its generic of big-selling overactive bladder drug Myrbetriq.

News

Lupin settles Myrbetriq patent spat with Astellas for $90m

Lupin will be able to keep its generic of Astellas' overactive bladder therapy Myrbetriq on the US market, after reaching a settlement agreement.

Oncology

Astellas’ banner year and focused R&D strategy, with Adam Pe...

At JPM2026, Astellas' chief strategy officer Adam Pearson walked pharmaphorum through the company’s four-pillared R&D strategy.

News

Padcev/Keytruda scores again in early bladder cancer

Pfizer and Astellas now have two studies supporting the use of Padcev with MSD's Keytruda as perioperative therapy for muscle-invasive bladder cancer.

News

EMA starts review of 'transformative' bladder cancer therapy

The EMA has started a review of a regimen based on Pfizer/Astellas' Padcev and MSD's Keytruda that is described as a game-changer for bladder cancer.

Astellas bets on Vir cancer drug, and other licensing deals

Zydus follows Lupin with Myrbetriq settlement deal

Lupin settles Myrbetriq patent spat with Astellas for $90m

Astellas’ banner year and focused R&D strategy, with Adam Pe...

Padcev/Keytruda scores again in early bladder cancer

EMA starts review of 'transformative' bladder cancer therapy

NHS "isn't delivering equitable care for rare diseases"

Using AI-driven synthetic personas to take your insights fur...

Astellas

Editor's Picks